Inceptionr LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Inceptionr LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,908 shares of the biotechnology company's stock, valued at approximately $1,326,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Simplify Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 84.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock worth $24,105,000 after buying an additional 88,474 shares during the period. Geode Capital Management LLC boosted its stake in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock valued at $211,910,000 after acquiring an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC grew its holdings in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after acquiring an additional 116,800 shares during the period. Larson Financial Group LLC raised its position in shares of Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock valued at $1,093,000 after acquiring an additional 8,249 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Sarepta Therapeutics by 30.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 78,244 shares of the biotechnology company's stock worth $9,772,000 after purchasing an additional 18,095 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Remove Ads

Sarepta Therapeutics Stock Down 3.2 %

Shares of NASDAQ SRPT traded down $3.34 during mid-day trading on Monday, hitting $99.69. The company had a trading volume of 1,639,059 shares, compared to its average volume of 923,232. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The firm has a 50-day simple moving average of $114.11 and a two-hundred day simple moving average of $121.27. The company has a market capitalization of $9.67 billion, a PE ratio of 79.75 and a beta of 0.79. Sarepta Therapeutics, Inc. has a one year low of $98.82 and a one year high of $173.25.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on SRPT shares. StockNews.com lowered Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Royal Bank of Canada cut their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a report on Wednesday, November 27th. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Sarepta Therapeutics in a research report on Tuesday, February 11th. They set a "hold" rating and a $136.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $170.41.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.